References
- Chiò A. ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 1999; 246 (Suppl 3): 1–5.
- Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Sub- committee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop con- tributors. J Neurol Sci 1994, 124 (suppl): 98–107.
- Miller RG, Munsat TL, Swash M et al. Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci 1999; 169 (1,2): 2–12.
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–591.
- Lacomblez L, Bensimon G, Leigh PN et al. Dose-ranging study in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–1431.
- Anderson FA jr, Miller RG. ALS care: a resource for measuring and improving ALS outcomes. Neurology 1996; 47 (Suppl 2): S113–S116.
- Jenkinson C, Swash M, Meininger V. The European Amyotrophic Lateral Sclerosis Health Profile Study. ALS-HPS Steer- ing Group. J Neurol Sci 1998; 160 (Suppl 1): S122–S126.